Fredun Pharmaceuticals Ltd

Fredun Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, moving from a fair to an expensive rating. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, invites a closer examination of the company’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector.

At Rs 1,197.7, sellers were still queuing — but there were no buyers willing to take the other side. Fredun Pharmaceuticals Ltd locked at its lower circuit of 9.8% on 16 Jun 2026, with unfilled sell orders and a frozen price.

Fredun Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair price territory. This change, coupled with robust financial metrics and a strong market performance relative to benchmarks, positions the micro-cap pharmaceutical company as an increasingly attractive proposition for investors seeking quality exposure in the Pharmaceuticals & Biotechnology sector.

Fredun Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 12 August 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 15 September 2026, providing investors with the latest comprehensive analysis.

Fredun Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 12 August 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 04 September 2026, providing investors with the latest insights into the company’s performance and outlook.

Fredun Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 12 August 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 24 August 2026, providing investors with the latest insights into the company’s performance and outlook.

Surging to an intraday peak of Rs 1600 on 17 Aug 2026, Fredun Pharmaceuticals Ltd has marked a remarkable milestone by hitting a fresh 52-week high. This achievement caps a spectacular 331.17% rally over the past year, vastly outperforming the Sensex’s decline of 3.60% during the same period.

After opening with a 3.37% gap up, Fredun Pharmaceuticals Ltd touched a fresh all-time high of Rs 1,600 on 17 Aug 2026, extending its remarkable rally that has seen the stock surge over 344% in the past year, vastly outperforming the Sensex and its sector peers.

Surging to an intraday peak of Rs 1599.9 on 14 Jun 2026, Fredun Pharmaceuticals Ltd has marked a remarkable milestone by hitting a fresh 52-week high. This rally comes amid a sustained four-day gain that has propelled the stock up by 26.11%, significantly outpacing its sector by 2.69% today alone.

Fredun Pharmaceuticals Ltd has reached a significant milestone by touching an all-time high price of Rs. 1,599.90 on 14 August 2026, marking a remarkable achievement in its market journey. The stock’s sustained upward momentum reflects the company’s robust financial performance and strong market positioning within the Pharmaceuticals & Biotechnology sector.

Surging past its previous peaks, Fredun Pharmaceuticals Ltd touched a fresh 52-week high of Rs 1464.95 on 13 Aug 2026, marking a remarkable rally from its 52-week low of Rs 338.73. This milestone caps a sustained upward momentum driven by a confluence of strong technical indicators and robust price action over recent sessions.

Extending its winning streak to three consecutive sessions, Fredun Pharmaceuticals Ltd surged to a fresh all-time high of Rs 1,464.95 on 13 Aug 2026, outperforming its sector and the broader market by a wide margin.

Fredun Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Strong Buy to Buy as of 12 August 2026. This adjustment primarily reflects a reassessment of the company’s valuation metrics, despite its robust financial performance and positive technical indicators. The revised Mojo Score stands at 77.0, signalling a solid but more cautious outlook for investors.

Fredun Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, moving from a fair to an expensive rating, reflecting a significant change in price attractiveness. This development comes amid robust stock performance and evolving market dynamics within the Pharmaceuticals & Biotechnology sector.

With a surge to Rs 1400 on 12 Aug 2026, Fredun Pharmaceuticals Ltd has reached a new 52-week high, marking a remarkable rally from its low of Rs 338.73. This milestone reflects a sustained momentum driven by a confluence of bullish technical indicators and robust price action, even as the broader market experienced a sharp reversal.

Extending its recent rally, Fredun Pharmaceuticals Ltd surged 5.71% on 12 Aug 2026 to close at Rs 1,349, marking a fresh all-time high. This milestone caps a remarkable run that has seen the stock outperform the Sensex by a wide margin over multiple timeframes.